• Title/Summary/Keyword: FGF271

Search Result 5, Processing Time 0.016 seconds

Phytoestrogenic Effects of Combined Plant Extracts on the Change of Bone Metabolism of OVX Rats (복합 생약추출물의 식물성 에스트로겐 활성이 OVX rat에 미치는 골대사 변화)

  • Kim, Soo-Nam;Li, Yong-Chun;Xu, Hong-De;Yi, Dong-Geun;Kim, Min-Seop;Lee, Sung-Pyo;Yi, Kwon-Taek;Lee, Jae-Kyoung;Kim, Jae-Soo;Kwon, Myung-Sang;Chang, Pahn-Shick;Kwak, Bo-Yeon
    • Korean Journal of Food Science and Technology
    • /
    • v.40 no.3
    • /
    • pp.316-320
    • /
    • 2008
  • This study examined the combined plant extracts (FGF271) of Estromon in ovariectomized (OVX) rats to determine whether Estromon's significant clinical improvement effects on menopausal symptoms are predominantly due to the phytoestrogenic action of the combined extracts. The results showed that all three FGF271-treated groups had significantly improved serum osteocalcin levels as compared to the control group (p<0.05). In addition, all FGF271- and Estromon-treated groups had increases in femoral bone mineral density (FBMD) (p<0.05), and the increase in the FGF271 group was dose-dependent. A pairwise comparison of the FGF271- and Estromon-treated groups receiving the same dosage of FGF271 indicated that there was no significant difference between the groups. Therefore, the FBMD increases that occurred in the Estromon groups were solely attributable to the phytoestrogenic effects of FGF271. It was conclude that the phytoestrogenic effects of Estromon, as shown in clinical studies, are predominantly caused by FGF271, the mixed extracts of Cynanchum wilfordii, Phlomis umbrosa, and Angelica gigas.

Effect of Plant Extract [FGF271] on Estrogen Replacement (식물유래 추출물(FGF271)의 여성호르몬 대체 효과)

  • 김재수;박준홍;조한성;박점석;홍억기
    • KSBB Journal
    • /
    • v.17 no.4
    • /
    • pp.409-415
    • /
    • 2002
  • A certain group of phytochemicals such as isoflavone have been proven to act as a phytoestrogen. After thorough the study of different bibliographic herbs excluding soybeans, dates, pomegranates, and other publicized plants, three different edible herbs by Korean Food Regulation were extracted for the animal study on the effect of estrogen replacement. The herbal extract(FGF271) has been orally administered into 51 weeks old partial ovariectomized rats for 5 weeks with the different dosages of 100 and 1,000 mg/kg, respectively. It was observed that 1) serum estrogen level was increased in both 100 and 1,000 mg/kg group, 2) the distension of uterus was made dose dependently and significantly different in 1,000 mg/kg group (p.0.05) from control in the gross findings, 3) the weight of uterus was increased in 1,000 mg/kg group, and 4) the action on reproductive tissues was clear in the microscopic findings in terms of hyperplasia of endometrial epithelial cell, cystic change of submucosa, dilatation of uterus (significantly increased in 1,000 kg/mg), and follicular cystic changes in ovary. As a result, FGF271 seemed to act as a phytoestrogen by inducing the change in ovary and uterus and by increasing the serum estrogen concentration.

Effect and Safety of Replacement Therapy for PMS〔post-Premenopausal Syndrome〕 (PMS 〔post-/Premenopausal Syndrome〕 여성에 대한 대체요법의 유효성 및 안전성)

  • 이득주;홍억기;김재수;조한성;한인권
    • KSBB Journal
    • /
    • v.19 no.1
    • /
    • pp.83-87
    • /
    • 2004
  • This research was designed to investigate the effects of Estromon including FGF271 (Female Growth Factor 271) which was developed as a phytoestrogen for post- and pre-menopausal syndrome (PMS). The oral administration of two capsules of Estromon twice a day for 3 months significantly improved PMS (Post-/Premenopausal Syndrome) about 5 times more than placebo group (OR=5.04, 95% C.1. 1.40-18.14). In the group of 24 patients having taken Estromon, the concentration of alkaline phosphatase asn the bone marker decreased by -9.3${\pm}$9.5 IU/L after 3 months with a statistic significance. Since the concentration of osteocalcin as the other bone marker also decreased in more patients in Estromon group than in placebo group, the bone density might be expected to be improved in long-term treatment. Serum human growth hormone level increased in 17 out of 24 patients. Triglycerides decreased by -8.0${\pm}$40 (mg%) after 1 month and by -4.4${\pm}$36 (mg%) after 3 months in Estomon group while triglycerides increased in both cases in placebo group (p.0.01). Therefore, PMS patients might benefit from Estromon as a phytoestrogen supplement without any serious side effects.

Contraction Behavior of Collagen Gel and Fibroblats Activity in Dermal Equivalent Model

  • Yang, Eun-Kyung;Lee, Doo-Hoon;Park, Sue-Nie;Choe, Tae-Boo;Park, Jung-Keug
    • Journal of Microbiology and Biotechnology
    • /
    • v.7 no.4
    • /
    • pp.267-271
    • /
    • 1997
  • We developed a dermal equivalent (DE) which was engineered using human dermal fibroblasts and a matrix of collagen gel. The in vitro construction of the DE was accomplished by casting a porcine collagen type I solution plus concentrated medium with isolated and cultured fibroblasts. These constructs were attached to culture dishes or left floating in culture medium. Contraction of attached gels results in decreased gel thickness without a change in gel diameter, and contraction of floating gels results in decreased gel thickness and diameter. After contraction, there was no increase in cell number in floating gels, but cells in attached gels began to increase after about 4 days of the lag phase in cell growth curve. At this lag phase, addition of fibroblast growth factor (FGF) at a concentration of $0.1{\mu}$/ml promoted cell proliferation in the attached collagen gels, but no effect in floating gels. These results indicate that the method of contraction had an influence on the extracellular matrix (ECM) organization, and this influenced not only cell growth but also fibroblast responsiveness to FGF. This suggests that attached collagen gel is more suitable as a dermal equivalent than the floating gel. And the final contracted area of attached gel is much larger than that of the floating gel since floating gel is contracted in all directions but attached gel is contracted only vertically.

  • PDF

Human Amniotic Fluid Cells Support Expansion Culture of Human Embryonic Stem Cells (양수 세포를 이용한 인간배아줄기세포의 배양)

  • Kim, Hee-Sun;Seol, Hye-Won;Ahn, Hee-Jin;Oh, Sun-Kyung;Ku, Seung-Yup;Kim, Seok-Hyun;Choi, Young-Min;Kim, Jung-Gu;Moon, Shin-Yong
    • Clinical and Experimental Reproductive Medicine
    • /
    • v.31 no.4
    • /
    • pp.261-271
    • /
    • 2004
  • Objective: This study was performed to evaluate the possibility of prolonged culture of human embryonic stem cells (hESC; SNUhES2) on human amniotic fluid cells (hAFC), which had been storaged after karyotyping. Method: The hAFC was prepared for feeder layer in the presence of Chang's medium and STO medium (90% DMEM, 10% FBS) at $37^{circ}C$ in a 5% $CO_2$ in air atmosphere. Prior to use as a feeder layer, hAFC was mitotically inactivated by mitomycin C. The hESCs on hAFC were passaged mechanically every seven days with ES culture medium (80% DMEM/F12, 20% SR, bFGF). Results: The hAFC feeder layer support the growth of undifferentiated state of SNUhES2 for at least 59 passages thus far. SNUhES2 colonies on hAFC feeder appeared slightly angular and flatter shape as compared with circular and thicker colonies observed with STO feeder layer and showed higher level with complete undifferentiation in seven days. Like hESC cultured on STO feeders, SNUhES2 grown on hAFC expressed normal karyotype, positive for alkaline phosphatase activity, high telomerase activity, Oct-4, SSEA-3, SSEA-4, Tra-1-60 and Tra-1-81 and formed embryoid bodies (EBs). Conclusion: The hAFC supports undifferentiated growth of hESC. Therefore, these results may help to provide a clinically practicable method for expansion of hESC for cell therapies.